Prevalence of cancer as a comorbid in COVID-19 patients and their characteristics: a meta-analysis study.

Cancer patients are considered susceptible to coronavirus disease (COVID-19) due to an immunosuppressive state. This study determined the prevalence of cancer as a comorbid in COVID-19 patients, severe events, case fatality rate, history of anticancer therapy associated with severe events, and type of cancer in cancer patients with COVID-19 in the world. This study used a meta-analysis study approach, sourcing studies from various countries related to cancer and COVID-19. Inclusion and exclusion criteria were established to select studies. A PRISMA flowchart was presented to assess the selection process. Data from inclusion studies were analyzed using Review Manager 5.4.  The prevalence of cancer as a comorbid in COVID-19 patients was 4.63% (95% CI, 3.78-5.49%) worldwide. The lowest prevalence was the Asian study group with 2.36% (95% CI, 1.86-2.87%) and the highest prevalence was the European study group with 10.93% (95% CI, 6.62-15.24%). About 43.26% (95% CI, 34.71-51.80%) of COVID-19 patients with cancer as comorbid experienced severe events of COVID-19. In total, 58.13% (95% CI, 42.79-73.48%) of COVID-19 patients with cancer as a comorbid who in the last month had a history of anticancer therapy experienced severe events. The prevalence of lung cancer in cancer patients with COVID-19 was 20.23% (95% CI, 7.67-32.78%). Forest plots are also presented related to the results of meta-analysis research.  High prevalence of cancer as a comorbid among COVID-19 patients indicates the susceptibility of cancer patients to SARS-CoV-2 infection. Cancer as a comorbid in COVID-19 patients and use of anticancer therapy increase severe events of COVID-19.